Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)stock surged 24.52% to $2.59 in the late hours last night after its Topline results have been announced from the Phase’s low dose cohort 2a ‘AMPITION’ clinical trial of CRV431, a novel cyclophilin inhibitor orally administered once daily.Phase 2a study of CRV431 is continuing at a higher dose of 225 mg, with CRV431 patient dosing expected in Q1-2021.
A CRV431 study called the AMBITION trial will be conducted among patients with moderate-to-severe fibrosis and NASH evidence.Researchers at 10 U.S. sites are administering 75 mg of CRV431 once-daily for 28 days in this study. An ongoing second cohort of 225 mg CRV431 (high dose) is being administered. We expect to have final results from both dosing cohorts once the high dose group has completed active dosing, followed by a 14-day observation period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.